Print-friendly View
Resources for Health Professionals and Patients
| Review: Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug | |
Attached file: |
(Russian, 284.8 kb)
Review: Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug
|
Link to document(s) | http://www.ncbi.nlm.nih.gov... |
Author(s): | Hicks C. et al. |
Document type: | Literature Reviews |
Language: | English, Russian |
Original language of document: | Russian |
Primary area(s) of focus: | HIV/AIDS |
Secondary areas of focus: | Client advocacy - human rights protection and legal support, Emergency financial assistance |
Submited by: | Victor Stanilevskiy |
Material written specifically for patients: | No |
Date of entry: | September 13, 2006 |
Pages: | 3 |
| Treatment options for HIV-1 infected individuals who have received extensive previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non-peptidic protease inhibitor tipranavir co-administered with ritonavir plus an optimised background regimen with that of an investigator-selected ritonavir-boosted comparator protease inhibitor (CPI-ritonavir) in such patients. | |
Overall user rating: | Not yet reviewed |
